Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
The Lancet. Respiratory Medicine|May 15, 2016
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studiesHector G Ortega, Steven W Yancey, Bhabita Mayer, et al.
Respiratory Medicine|April 22, 2017
Qualitative evaluation of the St George's Respiratory Questionnaire in patients with severe asthmaLinda M Nelsen, Miriam Kimel, Lindsey T Murray, et al.
The New England Journal of Medicine|September 9, 2014
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthmaElisabeth H Bel, Sally E Wenzel, Philip J Thompson, et al.
Respiratory Research|June 23, 2021
Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trialsCatherine Lemiere, Camille Taillé, Jason Kihyuk Lee, et al.
Allergy and Asthma Proceedings|February 20, 2010
Comparative effect of body mass index on response to asthma controller therapyE Rand Sutherland, Carlos A Camargo, William W Busse, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 27, 2010
Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukastCarlos A Camargo, Louis-Philippe Boulet, E Rand Sutherland, et al.
The Journal of Allergy and Clinical Immunology|October 12, 2016
Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthmaSteven W Yancey, Hector G Ortega, Oliver N Keene, et al.
Allergy and Asthma Proceedings|February 20, 2010
Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitisRohit K Katial, John J Oppenheimer, Nancy K Ostrom, et al.
American Journal of Respiratory and Critical Care Medicine|November 14, 2009
Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionateEugene R Bleecker, Harold S Nelson, Monica Kraft, et al.
ERJ Open Research|January 17, 2022
Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMETMark C Liu, Elisabeth H Bel, Oliver Kornmann, et al.
Pageof 7